Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PTS100 in Primary Hepatocellular Carcinoma
NCT03447951Phase 2Recruiting
- Sponsor
- Gongwin Biopharm Holdings Co., Ltd.
- Start
- Jun 2018
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of para-toluenesulfonamide in hepatocellular carcinoma (HCC) (2 arms), sponsored by Gongwin Biopharm Holdings Co., Ltd. Primary endpoint: Objective Response Rate. Started Jun 2018; status: recruiting.
02
Drugs
para-toluenesulfonamide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03447951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447951.